Ovarian clear cell cancer

This study tests whether a combination of two immune-boosting drugs (nivolumab and ipilimumab) works better than nivolumab alone for people with advanced clear cell cancers of the ovary, fallopian tube, peritoneum, or other areas. About 46 participants will receive one of the two…

This phase 2 study tests two drugs, sunitinib and temsirolimus, in 137 people with advanced rare tumors that have no cure. The goal is to see if these drugs can shrink tumors or slow their growth. Participants take one of the two drugs, and researchers measure how long the cancer…

This phase II trial is testing the drug tazemetostat in 62 patients whose ovarian or endometrial cancer has returned after prior treatment. The goal is to see if tazemetostat can shrink tumors or stop them from growing. Participants will receive the drug and be monitored for resp…

This phase 2 trial tests a new drug (ceralasertib) alone or combined with either olaparib or durvalumab in 174 people whose gynaecological cancer has returned. The study groups patients by their cancer type and whether they have a change in the ARID1A gene. The goal is to see if …

This phase 2 trial tests a drug called CYH33 in 93 women with recurrent ovarian, fallopian tube, or peritoneal clear cell carcinoma that has a specific genetic change (PIK3CA mutation). The drug works by blocking a protein that helps cancer grow. The main goal is to see if it shr…

This study tests two drugs, pembrolizumab and lenvatinib, in 30 people with recurrent clear cell ovarian cancer. The goal is to see if the combination can shrink tumors or slow cancer growth. Participants must have had at least one prior treatment and have measurable disease.